Peptides: GHRP-6 Overview
GHRP-6 was the first synthetic GHRP characterized in humans. It produces robust GH pulses at 100mcg but causes significant appetite stimulation via NPY/AgRP pathway activation.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | B | grade | Multiple human pharmacodynamic studies exist (PMID 8186706; 11238505; 9265876); no body composition RCTs |
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | hexapeptide | 6 amino acid hexapeptide; first GHRP synthesized and characterized; enkephalin-derived design |
| Hunger Onset | 20–30 | minutes post-injection | Significant appetite stimulation within 20–30 min of injection; resolves within 1–2 hours; strongest of all GHRPs |
| GH Pulse at 100mcg | ~4–5× | above baseline | GH pulse amplitude similar to GHRP-2 at equivalent dose; hunger and cortisol profile differentiates them |
| Standard Dose | 100–300 | mcg/injection | 2–3× daily; same protocol structure as other GHRPs; 300mcg is the practical upper limit per injection |
| Primary Indicated Use | Appetite stimulation + GH | use case | Preferred when deliberate appetite stimulation is desired: recovery from illness, underweight, or intentional caloric surplus |
| Cortisol/Prolactin | Dose-dependent | side effect | Similar cortisol/prolactin profile to GHRP-2; both increase above 300mcg per injection |
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide and the first growth hormone releasing peptide to be developed and characterized (Bowers CY, PMID 8186706). Derived from enkephalin by structure-activity relationship studies in the 1980s, GHRP-6 preceded the discovery of ghrelin by over a decade — it was only retroactively understood as a ghrelin receptor agonist after ghrelin was identified in 1999.
GHRP-6 produces robust GH pulses at 100mcg comparable to GHRP-2, but differs in two important ways: it causes stronger appetite stimulation (within 20–30 minutes of injection) and has slightly greater HPA axis activation at equivalent doses. These effects reflect GHRP-6’s broader ghrelin pathway mimicry, which activates both GH-releasing and orexigenic GHSR signaling more completely than GHRP-2 (PMID 9265876).
GHRP-6 vs GHRP-2 vs Ipamorelin: Comparative Profile
| Characteristic | GHRP-2 | GHRP-6 | Ipamorelin |
|---|---|---|---|
| Hunger stimulation (scale 1–5) | 2/5 | 4/5 | 1/5 |
| Cortisol increase (scale 1–5) | 3/5 | 3/5 | 1/5 |
| Prolactin increase (scale 1–5) | 2/5 | 2/5 | 1/5 |
| GH pulse amplitude at 100mcg | ~4–5× baseline | ~4–5× baseline | ~3–4× baseline |
| Half-life (subcut) | ~15–30 min | ~15–30 min | ~2 hours |
| Primary use case | GH optimization, moderate selectivity | GH + appetite stimulation; illness recovery | GH optimization, cleanest profile |
| Evidence grade | B | B | B |
Caloric Intake and the Hunger Problem
GHRP-6’s hunger effect is the primary practical concern for most users. Without dietary structure:
- Injection 3× daily can drive significant caloric surplus
- Each hunger episode peaks ~30 min post-injection and lasts ~1–2 hours
- At 300mcg 3×/day, three hunger episodes per day represent ~3–6 hours of elevated appetite daily
- Fat accumulation is possible if caloric surplus is chronic
For users seeking GH pulse amplification for body composition (fat loss or lean mass), this hunger side effect undermines the goal. Ipamorelin or GHRP-2 are preferred. GHRP-6 is appropriate when appetite stimulation is a desired outcome.
Historical Significance
GHRP-6 is historically the most important GHRP for scientific purposes. It established the GHRP pharmacological class before ghrelin’s existence was known, enabled characterization of GHSR, and formed the basis for subsequent structure-activity relationship work that led to more selective compounds (GHRP-2, ipamorelin, hexarelin). Most of the foundational human pharmacodynamic data on GHRPs uses GHRP-6 as the reference compound (PMID 8186706; PMID 9265876).
Legal Status
| Jurisdiction | Status | Schedule | Notes |
|---|---|---|---|
| USA | Research chemical | Unscheduled | Not FDA-approved; WADA prohibited (S2) for competitive athletes |
| UK | Not scheduled | None | Legal to possess; WADA prohibited under UKAD anti-doping rules |
| Australia | Prescription restricted | Schedule 4 (TGA) | ASADA prohibited; not commercially available without prescription |
| Canada | Gray market | No schedule | No approved DIN; WADA prohibited for athletes |
| EU | Generally unscheduled | Varies by country | No EMA approval; WADA prohibited for athletes |
Related Pages
Sources
- Bowers CY. GH releasing peptides — structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21-31. PMID 8186706
- Arvat E et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue. J Clin Endocrinol Metab. 2001;86(3):1169-74. PMID 11238505
- Ghigo E et al. Hypothalamic and extra-hypothalamic regulation of growth hormone secretion in humans. J Endocrinol Invest. 1997;20(5):259-78. PMID 9265876
Frequently Asked Questions
Who should consider GHRP-6 over GHRP-2 or ipamorelin?
GHRP-6 is specifically advantageous for users who want appetite stimulation alongside GH release — for example, individuals recovering from illness, surgery, or chronic conditions causing poor appetite and weight loss. For healthy adults primarily interested in GH optimization without significant appetite increase, GHRP-2 or ipamorelin are more appropriate choices.
How strong is the hunger effect from GHRP-6?
The hunger effect is significant and often described as intense, particularly at doses above 100mcg. It typically begins 20–30 minutes after injection and can drive substantial caloric intake if not consciously managed. Users who inject GHRP-6 pre-sleep (an optimal GH timing window) often report waking with elevated appetite or disrupted sleep due to hunger. This is one reason most protocols favor ipamorelin or GHRP-2 for pre-sleep injections.
Is GHRP-6 the most-studied GHRP in humans?
Yes. GHRP-6 was the first synthetic GHRP developed and characterized by Bowers in the 1980s (PMID 8186706), and it forms the basis of most foundational GHRP research. Most early human pharmacodynamic studies used GHRP-6, which is why its GH-releasing effects in humans are among the best-documented of all GHRPs.